Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase
Mitsuru Imamura, Jong-Seok Moon, Kuei-Pin Chung, Kiichi Nakahira, Thangamani Muthukumar, Roman Shingarev, Stefan W. Ryter, Augustine M.K. Choi, Mary E. Choi
Mitsuru Imamura, Jong-Seok Moon, Kuei-Pin Chung, Kiichi Nakahira, Thangamani Muthukumar, Roman Shingarev, Stefan W. Ryter, Augustine M.K. Choi, Mary E. Choi
View: Text | PDF
Research Article Cell biology Nephrology

RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase

  • Text
  • PDF
Abstract

Renal fibrosis is a common pathogenic response to injury in chronic kidney disease (CKD). The receptor-interacting protein kinase-3 (RIPK3), a regulator of necroptosis, has been implicated in disease pathogenesis. In mice subjected to unilateral ureteral obstruction–induced (UUO-induced) or adenine diet–induced (AD-induced) renal fibrosis, models of progressive kidney fibrosis, we demonstrate increased kidney expression of RIPK3. Mice genetically deficient in RIPK3 displayed decreased kidney fibrosis and improved kidney function relative to WT mice when challenged with UUO or AD. In contrast, mice genetically deficient in mixed-lineage kinase domain-like protein (MLKL), a downstream RIPK3 target, were not protected from UUO-induced kidney fibrosis. We demonstrate a pathway by which RIPK3 promotes fibrogenesis through the AKT-dependent activation of ATP citrate lyase (ACL). Genetic or chemical inhibition of RIPK3 suppressed the phosphorylation of AKT and ACL in response to TGF-β1 in fibroblasts. Inhibition of AKT or ACL suppressed TGF-β1–dependent extracellular matrix production and myofibroblast differentiation in fibroblasts. Pharmacological inhibition of ACL suppressed UUO-induced kidney fibrosis. RIPK3 expression was highly regulated in human CKD kidney. In conclusion, we identify a pathway by which RIPK3 promotes kidney fibrosis independently of MLKL-dependent necroptosis as a promising therapeutic target in CKD.

Authors

Mitsuru Imamura, Jong-Seok Moon, Kuei-Pin Chung, Kiichi Nakahira, Thangamani Muthukumar, Roman Shingarev, Stefan W. Ryter, Augustine M.K. Choi, Mary E. Choi

×

Figure 1

RIPK3 promotes kidney fibrosis in the UUO model.

Options: View larger image (or click on image) Download as PowerPoint
RIPK3 promotes kidney fibrosis in the UUO model.
WT (A–H) or Ripk3–/– mi...
WT (A–H) or Ripk3–/– mice (C–H) were subjected to sham operation or UUO, and kidneys were harvested at 7 days after surgery. (A) Ripk3 mRNA expression was analyzed by qRT-PCR. Gapdh was the standard (n = 7, WT Sham; n = 8, WT UUO). *P < 0.05 by Mann-Whitney test. (B) RIPK3 expression was determined by Western blot analysis. GAPDH was the standard (n = 3, WT Sham; n = 7, WT UUO). Dot plots represent densitometric analysis of Western blot data (mean ± SEM, 3 independent experiments). *P < 0.05 by Mann-Whitney test. (C) Kidney tissue lysates were subjected to Western blot analysis for α–smooth muscle actin (αSMA), type-I collagen (Col-I), and fibronectin (FN). GAPDH was the standard. Dot plots represent densitometric analysis of Western blot data (mean ± SEM, 3 independent experiments). *P < 0.05 compared with WT UUO mice by ANOVA with Newman-Keuls post-hoc test. (D) Kidney tissues were analyzed by qRT-PCR for Col1a1 and Acta2 mRNA expression. Gapdh was the standard. *P < 0.05 compared with WT UUO mice by ANOVA with Newman-Keuls post-hoc test (mean ± SEM, 3 independent experiments). (E and F) Kidney tissues were stained with (E) Masson’s trichrome or (F) immunostained for RIPK3. Representative images are shown. Tubular epithelial cells (arrowheads) and interstitial cells (arrows) are indicated. Scale bars: 100 μm. (G) Immunofluorescence staining for RIPK3 (red), vimentin (green), and Hoechst (blue). Scale bars: 10 μm. C–G; n = 6 for UUO; n = 3 for Sham. (H) Quantitative analysis of TUNEL-positive cells. The number of TUNEL-positive cells was counted in 5 random high-power fields (HPF) of the left kidney of the WT mice and Ripk3–/– mice 7 days after UUO or sham surgery. The dot represents the average of the number of TUNEL-positive cells per HPF for each mouse. WT Sham (n = 4), WT UUO (n = 7), Ripk3–/– Sham (n = 3), Ripk3–/– UUO (n = 6). *P < 0.05 compared with WT UUO mice by ANOVA with Newman-Keuls post-hoc test. All values represent mean ± SEM from 3 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts